The mission of Allegro Diagnostics is to provide the most timely, accurate, and comprehensive diagnosis to clinicians and patients about patient health.
Allegro Diagnostics, Inc. is a molecular diagnostics company using proprietary technology and bioinformatics to diagnose diseases of epithelial origin, such as lung cancer. Founded in 2006, the company received a seed Launch Award of $175,000 from the Boston University Office of Technology Development in July of 2007. In February of 2008, Allegro Diagnostics raised a $4 million A round of financing from Kodiak Venture Partners and Catalyst Health Ventures.
Allegro Diagnostics plans to develop and commercialize its gene biomarker technology, validated in the March 2007 edition of Nature Medicine. The company's work is based on the research of our founders, Jerome Brody, MD and Avrum Spira, MD, MSc, at the renowned Pulmonary Center at the Boston University School of Medicine. Allegro Diagnostics has developed a significant patent portfolio in the areas of gene expression, bioinformatics, and diagnostics. The company's initial products will target the lung cancer field for confirmation of presence or absence of lung cancer, disease characterization, and screening of high risk populations.